ArticleJournal of medicinal chemistry2019
Development of Covalent Ligands for G Protein-Coupled Receptors: A Case for the Human Adenosine A
Article in Journal of medicinal chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 45 citations in OpenAlex.
- 5-Amino- and 6-amino-uracils in the synthesis of various heterocycles as therapeutic agents: a review.RSC advances · 2025Review
- Ligand-directed covalent labelling of adenosine receptors.Purinergic signalling · 2025Article
- Molecular basis of ligand binding and receptor activation at the human ANature communications · 2025Article
- Advancing Covalent Ligand and Drug Discovery beyond Cysteine.Chemical reviews · 2025Review
- Advances in sulfonyl exchange chemical biology: expanding druggable target space.Chemical science · 2025Review
- Facile Synthesis of FimH Antagonist and Its Analogues: Simple Entry to ComplexACS medicinal chemistry letters · 2024Article
- Article
- Efficient Ligand Discovery Using Sulfur(VI) Fluoride Reactive Fragments.ACS chemical biology · 2023Article
- Goods and Bads of the Endocannabinoid System as a Therapeutic Target: Lessons Learned after 30 Years.Pharmacological reviews · 2023Review
- Article
- Technologies for Direct Detection of Covalent Protein-Drug Adducts.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Extended Applications of Small-Molecule Covalent Inhibitors toward Novel Therapeutic Targets.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Development of subtype-selective covalent ligands for the adenosine ARSC medicinal chemistry · 2022Article
- Irreversible Antagonists for the Adenosine AMolecules (Basel, Switzerland) · 2022Article
- International Union of Basic and Clinical Pharmacology. CXII: Adenosine Receptors: A Further Update.Pharmacological reviews · 2022Review
- Design and Characterization of an Intracellular Covalent Ligand for CC Chemokine Receptor 2.Journal of medicinal chemistry · 2021Article
- Molecular probes for the human adenosine receptors.Purinergic signalling · 2021Review
- G protein-coupled receptors: structure- and function-based drug discovery.Signal transduction and targeted therapy · 2021Review
- Covalent allosteric modulation: An emerging strategy for GPCRs drug discovery.European journal of medicinal chemistry · 2020Review
- Designing Chimeric Molecules for Drug Discovery by Leveraging Chemical Biology.Journal of medicinal chemistry · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of covalent ligands for G protein-coupled receptors (GPCRs) is not a trivial process. Here, we report a streamlined workflow thereto from synthesis to validation, exemplified by the discovery of a covalent antagonist for the human adenosine A
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.